Merck KGaA (OTCMKTS:MKKGY – Get Free Report) saw a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 46,022 shares, a drop of 68.5% from the October 15th total of 146,247 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 104,760 shares, the days-to-cover ratio is presently 0.4 days.
Merck KGaA Stock Up 1.5%
OTCMKTS MKKGY traded up $0.50 during trading hours on Friday, hitting $33.12. The company had a trading volume of 20,663 shares, compared to its average volume of 94,101. The firm’s 50 day moving average is $31.72 and its 200 day moving average is $30.08. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. Merck KGaA has a fifty-two week low of $23.73 and a fifty-two week high of $34.19. The company has a market capitalization of $21.40 billion, a price-to-earnings ratio of 17.07, a P/E/G ratio of 2.93 and a beta of 0.92.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on MKKGY shares. Zacks Research upgraded Merck KGaA from a “strong sell” rating to a “hold” rating in a report on Tuesday. UBS Group lowered shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. Six investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company currently has an average rating of “Hold”.
Read Our Latest Analysis on Merck KGaA
Merck KGaA Company Profile
Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.
See Also
- Five stocks we like better than Merck KGaA
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
